Literature DB >> 3789774

Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency.

R G Teepe, A W Broekmans, B J Vermeer, A M Nienhuis, E A Loeliger.   

Abstract

An elderly woman who had been receiving long-term oral anticoagulant therapy developed skin and subcutaneous fat necrosis on five repeated occasions of extreme hypocoagulability, associated with coinciding periods of congestive cardiac failure. In each episode, the skin necrosis developed within days after the prothrombin time (as determined with Thrombotest) exceeded 200 s (International Normalized Ratio greater than 5.4). Widespread thrombosis in the subcutaneous vasculature and interstitial bleeding, as observed in a skin biopsy specimen, were consistent with a diagnosis of coumarin necrosis. On two occasions, an acquired functional protein C deficiency was present. It is hypothesized that an imbalance between anticoagulant and procoagulant vitamin K-dependent factors contributed to the pathogenesis of coumarin-induced skin necrosis. This imbalance was related to repeated periods of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3789774

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

1.  Warfarin-Induced Skin Necrosis in the Presence of Acute Hepatic Injury and May-Thurner Syndrome.

Authors:  Carrie Tilton; Spencer Livengood; Jeremy Hodges; Jessica Marshall
Journal:  Hosp Pharm       Date:  2018-05-18

2.  Skin Necrosis Induced by Coumarin Congeners.

Authors:  Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2017-08-01

3.  Heterozygous protein C deficiency type I.

Authors:  B Kemkes-Matthes
Journal:  Blut       Date:  1989-04

4.  [The clinical importance of protein C and S deficiency for surgical patients].

Authors:  H Rabl; H Fruhwirth
Journal:  Langenbecks Arch Chir       Date:  1992

Review 5.  Cutaneous Drug Reactions in the Elderly.

Authors:  James W S Young; Neil H Shear
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 4.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.